By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators discuss new findings in Biotechnology. According to news reporting originating from Osaka, Japan, by NewsRx correspondents, research stated, "Human T-cell leukemia virus type 1 (HTLV-1), which causes adult T-cell leukemia (ATL) in humans, establishes a life-long latent infection. Current therapies are not very effective against HTLV-1-associated disorders."
Our news editors obtained a quote from the research from the Osaka Prefectural Institute of Public Health, "A novel therapeutic approach may help to combat HTLV-1 infection. A molecular therapy that targets the proviral genome is favorable because the therapeutic effect occurs specifically in HTLV-1-infected cells, regardless of whether they express viral genes. In this proof-of-concept study, we developed a therapeutic molecule based on zinc finger nuclease (ZFN) to achieve this goal. We designed a ZFN that specifically recognized conserved region of HTLV-1 long terminal repeat (LTR) and introduced it into various HTLV-1-positive human T-cell lines, including HTLV-1-transformed and ATL-derived cell lines. The ZFN disrupted the promoter function of HTLV-1 LTR and specifically killed HTLV-1-infected cells. We also showed a potential approach of this therapeutic molecule to remove the proviral genome from HTLV-1-infected cells, something that has not been possible before. The therapeutic effect of ZFN was confirmed in an in vivo model of ATL. This strategy may form the basis of a therapy that can eradicate HTLV-1 infection."
According to the news editors, the research concluded: "Similar approaches can be used to target other malignancy-associated viruses."
For more information on this research see: A novel therapeutic molecule against HTLV-1 infection targeting provirus. Leukemia, 2013;27(8):1621-1627. Leukemia can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Leukemia - www.nature.com/leu/)
The news editors report that additional information may be obtained by contacting A. Tanaka, Osaka Prefectural Inst Public Hlth, Div Virol, Dept. of Infect Dis, Osaka 5370025, Japan. Additional authors for this research include S. Takeda, R. Kariya, K. Matsuda, E. Urano, S. Okada and J. Komano (see also technology.html">Biotechnology).
Keywords for this news article include: Asia, Biotechnology, Osaka, Japan, Therapeutics, Leukemia Gene Therapy
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC